Cargando…
Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
BACKGROUND: The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first time that patients were completely free of viable tumor. CASE PRESENTATION: Two pa...
Autores principales: | Schliep, Stefan, Agaimy, Abbas, Cavallaro, Alexander, Kiesewetter, Franklin, Schuler, Gerold, Heinzerling, Lucie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767974/ https://www.ncbi.nlm.nih.gov/pubmed/29332608 http://dx.doi.org/10.1186/s40425-017-0309-3 |
Ejemplares similares
-
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013) -
Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
por: Krückel, Annika, et al.
Publicado: (2019) -
The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020) -
Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
por: Kirchberger, Michael Constantin, et al.
Publicado: (2018) -
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
por: Tomsitz, Dirk, et al.
Publicado: (2022)